Efficacy of mesna in preventing further cyclophosphamide‐lnduced hemorrhagic cystitis
- 1 January 1988
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 16 (6) , 372-374
- https://doi.org/10.1002/mpo.2950160603
Abstract
Mesna is a sulfhydryl compound that reacts with the metabolites of cyclophosphamide that are excreted in the urine and may produce bladder wall irritation. Mesna is converted in the blood to a biochemically inactive compound that is reduced back to mesna in the kidneys. In this way it has the potential to protect the bladder mucosa without interfering with the antineoplastic effect of cyclophosphamide. Twenty-two patients who had developed hemorrhagic cystitis from cyclophosphamide were treated again with cyclophosphamide and mesna prophylaxis. A total of 68 cycles of cyclophosphamide were given with mesna, with a median of three cycles per patient. A recurrence of cystitis was prevented in all but one patient. Thus, mesna is effective in preventing recurrent cystitis in patients receiving further cyclophosphamide.Keywords
This publication has 8 references indexed in Scilit:
- The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.Journal of Clinical Oncology, 1987
- Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostaticsZeitschrift für Krebsforschung und Klinische Onkologie, 1986
- Urinary Complications of Cyclophosphamide TherapySouthern Medical Journal, 1983
- High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcomaCancer Chemotherapy and Pharmacology, 1983
- Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatmentCancer Chemotherapy and Pharmacology, 1982
- Cyclophosphamide cystitis—Identification of acrolein as the causative agentBiochemical Pharmacology, 1979